Please assess the completion status of the following clinical trial:

Trial Title: Impella CP With VA ECMO for Cardiogenic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cardiogenic shock: Including refractory to conventional therapy, including systolic blood pressure \< 90mm Hg, Cardiac Index \< 1.8 or a cardiac index \< 2.0 on moderate to high doses of inotropes and vasopressors for greater than 30 mins, or systemic signs of tissue hypoxia.~* Post-acute myocardial infarction cardiogenic shock: excluding mechanical complications requiring surgical intervention after extracorpeal membrane oxygenator (ECMO) such as post-ischaemic ventricular septal defect (VSD).~* Drug overdose-induced cardiogenic shock.~* Early graft failure: post orthotropic heart transplantation cardiogenic shock, excluding immediate intra-operative failure.~* Acute on chronic cardiomyopathy with progressive shock and decompensation unresponsive to medical therapies.~Exclusion Criteria:~* Recent Significant Pulmonary Embolus~* Moderate to severe aortic valve insufficiency (AI)~* Ongoing significant sepsis~* Severe pulmonary hypertension \& shock~* Hypothermia~* Post-cardiotomy cardiogenic shock~* Continuous cardiopulmonary resuscitation (CPR) \>20-30 minutes, except if neurological status is satisfactory~* Transfer from outside hospital on VA ECMO or with history of CPR~* Listed for cardiopulmonary transplantation or being evaluated for cardiopulmonary transplantation or permanent mechanical circulatory support~* Known or suspected chronic heart failure with echocardiogram documenting left ventricular diastolic diameter \>6.5cm~* Known or suspected chronic heart failure with echocardiogram documenting left ventricular ejection fraction \< 25%~* Mechanical aortic valve replacement~* Presence of left ventricular thrombus~* Pre-existing Impella 2.5, CP, 3.5 or 5.0~* Cardiogenic shock due to primary respiratory failure~* Mechanical complications requiring surgical intervention after ECMO such as post-ischaemic VSD.~* Severe liver failure~* Active malignancy~* Acute aortic dissection~* Intracranial hemorrhage~* Neurological injury including recent cerebrovascular accident or suspected severe neurologic injury

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): VA-ECMO alone per standard clinical protocol.
- Experimental (Type: EXPERIMENTAL): VA-ECMO with early institution of Impella CP LV venting

Based on this trial design, predict the completion outcome and termination type (if applicable).